Merck/Schering-Plough Zetia-statin combo data
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryEzetimibe 10 mg add-on therapy with pravastatin (Bristol-Myers Squibb's Pravacol) shows 13% greater reduction in LDL-C than pravastatin alone (37.7% for the combo vs. 24.3% for pravastatin) in a 538-patient study, Merck and partner Schering-Plough report May 9 at the World Congress of Cardiology in Sydney, Australia. A 548-patient study of add-on therapy with lovastatin (Merck's Mevacor) found a 14% greater reduction for the combo (39% vs. 24.7%). The two Phase III trials are included in a pending NDA for Zetia monotherapy and combo therapy, along with Phase III combo trials with simvastatin (Merck's Zocor), atorvastatin (Pfizer's Lipitor), and a study including a variety of statins (Pharmaceutical Approvals Monthly, April 2002, p. 21). FDA action is expected by year-en
You may also be interested in...
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.
Bioresearchers at the Centers for Disease Control and Prevention are hoping that diagnostic platforms previously used to develop tests for outbreaks of other epidemic respiratory diseases, including SARS and MERS, can be built on to develop new diagnostics to detect more cases in the current coronavirus outbreak, US infectious disease authorities say. This comes as more patients are monitored around the US for the disease, and a Chicago woman returning from China tests positive.